Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Advanced Solid Tumours 5Squamous Cell Carcinoma of Head and Neck 3Solid Tumors 2Small Cell Lung Carcinoma 2Ovarian Neoplasms 2Leukemia, Myeloid, Acute 2Glioblastoma 2Vaginal Neoplasms 1Uterine Cervical Neoplasms 1Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Neoplasm Metastasis 1Myelodysplastic Syndromes 1Muscle Invasive Bladder Cancer 1Meningeal Carcinomatosis 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Laryngeal Neoplasms 1Head and Neck Neoplasms 1Gliosarcoma 1Esophageal Squamous Cell Carcinoma 1Esophageal Neoplasms 1Diffuse Intrinsic Pontine Glioma 1Colorectal Neoplasms 1Carcinoma, Endometrioid 1Brain Neoplasms 1Blast Crisis 1Astrocytoma 1Advanced Solid Tumors 1Adenocarcinoma Of Esophagus 1

Interventions

pembrolizumab 59Gemcitabine 37Biopsy 33Specimen Handling 32Paclitaxel 30Magnetic Resonance Spectroscopy 30Nivolumab 29Cisplatin 26Carboplatin 25Irinotecan 24Cyclophosphamide 23Fluorouracil 22Bevacizumab 22Docetaxel 21Oxaliplatin 19Leucovorin 18Ipilimumab 17Cetuximab 17Capecitabine 17130-nm albumin-bound paclitaxel 16Everolimus 15Albumin-Bound Paclitaxel 15Trastuzumab 13olaparib 12Pemetrexed 12Erlotinib Hydrochloride 12spartalizumab 11Sorafenib 11Radiosurgery 11trastuzumab deruxtecan 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Neoplasm Metastasis × adavosertib × Clear all
NCT04197713 2026-04-29

Testing the Sequential Combination of the Anti-cancer Drugs Olaparib Followed by Adavosertib (AZD1775) in Patients With Advanced Solid Tumors With Selected Mutations and PARP Resistance, STAR Study

National Cancer Institute (NCI)

Phase 1 Active not recruiting
13 enrolled 13 charts
Tumor-Agnostic

Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡